Clinical Trial: A Phase II Study of Radscopal Radiotherapy Combined with Immunotherapy as First-Line Treatment for Chemotherapy-Ineligible Patients with De Novo Metastatic Nasopharyngeal Carcinoma (RADIANCE) (China)

China, Aug. 19 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase II Study of Radscopal Radiotherapy Combined with Immunotherapy as First-Line Treatment for Chemotherapy-Ineligible Patients with De Novo Metastatic Nasopharyngeal Carcinoma (RADIANCE)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130265

Registration Time: 2026/08/18

Type: Interventional study

Primary Sponsor: Sun Yat-sen University Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336653

Published by HT Digital Content Services with permission from Health Daily Digest....